2022 marks the Tenth Anniversary of TransCelerate. 150 current and past members, contributors, and other industry stakeholders from around the world convened at the Franklin Institute in Philadelphia on October 6, 2022, to celebrate.
At its founding, TransCelerate’s goal was to tackle five persistent issues in clinical trials: development of a shared user interface for investigator site portals, mutual recognition of study site qualification and training, development of risk-based site monitoring approach and tools, providing support to CDISC to aid the development of clinical data standards, and establishment of a comparator drug supply network. Today, we boast 30+ initiatives and our tools span preclinical, clinical, and drug safety in R&D.
This milestone presented an opportunity for reflection and learn from our contributors and other industry stakeholders how they think TransCelerate is making a lasting, positive mark on the R&D ecosystem. Additionally, January 2023 will see current COO Janice Chang assume the position of TransCelerate CEO, as Dalvir Gill retires after over 30 years of service to the life sciences industry, 10 of them as TransCelerate’s lead executive.
As we usher in the next decade of our evolution and contributions, TransCelerate has undergone a strategic rebrand to better encompass the value and innovation that we bring to the biopharma ecosystem through our collaboration and tools that help to transform how drugs are developed.
Laying the Foundation
Last fall, TransCelerate interviewed approximately 250 people that were integral to our history. This group included employees, current and former member contributors, Health Authorities, CROs, tech vendors, and other industry consortia. The answers were then blinded and aggregated into top themes.
The results showed that as we grew, the industry still thought of us as a solely clinical organization. TransCelerate has value across all lifecycles and publicly available solutions beyond clinical, and our new brand and messaging needed to reflect this finding.
TransCelerate is a trailblazer among biopharmaceutical collaboratives transforming the biopharmaceutical R&D community. As a result, the new brand encompasses the concept of “Accelerating,” whether it’s “Accelerating Collaboration,” “Accelerating Innovation,” or “Accelerating Solutions.”
The new name, tagline, messaging, and branding elements reflect the essence of how we convene essential parties around the world—whether it’s sponsors, sites, CROs, patients, or Health Authorities—to “Accelerate Answers” to R&D’s most pressing drug development needs and get medicines to patients faster. We would not be successful without our membership and other global organizations working alongside us to challenge themselves and inspire each other to break down walls and find a common purpose in improving how the biopharma community functions and making patients’ lives better.
The essence of TransCelerate—our vision, mission, and values—remains unchanged. The capstone of this project is a new About Us video that distills our value to the R&D ecosystem. Watch it below and stay tuned for the next decade of collaboration and innovation.
Related Blog Posts
2022 was a noteworthy year for TransCelerate BioPharma, marking the tenth anniversary of our organization. We started with 10 pioneering companies and just five carefully selected projects. Today we are comprised of 20 of the largest multinational biopharmaceutical companies that have demonstrated the ability to create sustainable change in the drug development ecosystem. Our 2022…
This October, TransCelerate will mark its 10-year anniversary. As we reflect upon the past decade, we have asked several of our senior leaders and members of our Board of Directors to share their perspectives on the impact of TransCelerate’s work and collaboration as well as our successes and impact within the R&D ecosystem. To begin this series, TransCelerate…
Despite closing out a second year of the COVID-19 pandemic, the R&D ecosystem continued to carry its momentum to modernize clinical trials and make them even more patient-friendly, accessible, and safe. Our 20 Member Companies worked diligently together to create solutions that can transform information flow in clinical development, how sponsors and sites interact with…